Chempartner Pharmatech Co., Ltd.

Equities

300149

CNE100000Y27

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
4.82 ^CNY	+1.90%		+2.99%	-36.99%

Jan. 10	Chempartner Pharmatech Announces Resolutions of the The First Extraordinary General Meeting of Shareholders 2024.	CI
2023	MEGA STAR CENTRE LIMITED Announces Nominee to the Board of Chempartner Pharmatech.	CI

Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on January 22, 2021.

January 21, 2022 at 04:04 am EST

From January 1, 2022 to January 21, 2022, the company has repurchased 362,900 shares, representing 0.07% for CNY 5.06 million. With this, the company has completed the repurchase of 1,812,900 shares, representing 0.36% for CNY 25.5 million under the buyback announced on January 22, 2021.

Latest news about Chempartner Pharmatech Co., Ltd.

Chempartner Pharmatech Announces Resolutions of the The First Extraordinary General Meeting of Shareholders 2024.	Jan. 10	CI
MEGA STAR CENTRE LIMITED Announces Nominee to the Board of Chempartner Pharmatech.	Dec. 29	CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
ChemPartner PharmaTech CFO Steps Down	23-10-09	MT
Chempartner Pharmatech Co., Ltd.(XSEC:300149) added to S&P Global BMI Index	23-09-18	CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Chempartner Pharmatech Co., Ltd.(XSEC:300149) dropped from S&P Global BMI Index	22-12-19	CI
Chinese Shares End Mixed; ChemPartner Falls 6% as Chairman Assumes CEO Role	22-12-14	MT
ChemPartner PharmaTech Appoints Chairman as CEO; Shares Rise 4%	22-12-14	MT
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd..	22-06-08	CI
Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding	22-05-07	CI
Jiangmen Xinhui Hefeng Trading Co., Ltd. completed the acquisition of Quantum Hi-Tech Health Technology Co., Ltd from Chempartner Pharmatech Co., Ltd..	22-05-04	CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Tate & Lyle To Pay $237 Million For Chinese Prebiotic Dietary Fiber Business	22-03-31	MT
Tate & Lyle Investments Limited agreed to acquire Quantum Hi-Tech Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. for CNY 1500 million.	22-03-30	CI
Porton Pharma Solutions Ltd. agreed to acquire Kaihui Pharmaceutical Co., Ltd. from Chempartner Pharmatech Co., Ltd. for CNY 241 million.	22-03-08	CI
Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on January 22, 2021.	22-01-21	CI
Chempartner Pharmatech Co., Ltd.'s Equity Buyback announced on January 22, 2021, has expired with 1,812,900 shares, representing 0.36% for CNY 25.5 million.	22-01-20	CI
Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on January 22, 2021.	22-01-05	CI
Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on January 22, 2021.	21-10-12	CI

Chart Chempartner Pharmatech Co., Ltd.

Duration

Period

More charts

Company Profile

ChemPartner PharmaTech Co Ltd, formerly Quantum Hi-tech China Biological Co Ltd, is a China-based company principally engaged in the research, development, production, and sales of fructooligosaccharides and other prebiotics. The Company's main products include fructooligosaccharides and galactooligosaccharides. The Company owns brands names of FOS and GOS. The Company's products are mainly used in nutrition and health products, dairy products, beverages, baked goods, functional candy and snack foods. The Company distributes its products mainly in domestic market, with South China as its main market.

Sector

Biotechnology & Medical Research

Calendar

2024-04-25 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHEMPARTNER PHARMATECH CO., LTD.	-36.99%	325M
IQVIA HOLDINGS INC.	+0.64%	43.84B
MODERNA, INC.	+5.53%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.07%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.72%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.44%	12.29B
MEDPACE HOLDINGS, INC.	+26.01%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.66%	11.15B

Other Biotechnology & Medical Research